The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.
 
Roy S. Herbst
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Lilly; Merck; Pfizer
Research Funding - Genentech; Merck
 
Ian Chau
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tyrogenex (Inst)
 
Rafael Santana-Davila
Consulting or Advisory Role - ARIAD; Boehringer Ingelheim
Research Funding - Abbvie (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); Genentech (Inst); Lilly (Inst)
 
Emiliano Calvo
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Celgene; Cerulean Pharma; EUSA Pharma; Janssen-Cilag; Nanobiotix; Novartis; Pierre Fabre; PsiOxus Therapeutics; Seagen
Speakers' Bureau - Novartis
Research Funding - Abbvie; Amcure; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; H3 Biomedicine; Incyte; Janssen Oncology; Kura Oncology; Lilly; Loxo; Macrogenics; Menarini; Merck; Merck Serono; Merus; Millennium; Nanobiotix; Nektar; Novartis; Pfizer; PharmaMar; Principa Biopharma; PsiOxus Therapeutics; Puma Biotechnology; RigonTEC; Roche/Genentech; Sanofi; Synthon; Taiho Pharmaceutical; Tesaro
Travel, Accommodations, Expenses - Celgene; Novartis
 
Nicolas Penel
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag
 
Juan Martin-Liberal
No Relationships to Disclose
 
Andres O. Soriano
No Relationships to Disclose
 
Philippe Alexandre Cassier
Honoraria - Amgen; Blueprint Medicines; Novartis; Roche/Genentech
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Novartis; Roche
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Octimet; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Nicolas Isambert
Travel, Accommodations, Expenses - AstraZeneca; Celgene; MedImmune; Novartis; PharmaMar; Roche/Genentech
 
Ryan Widau
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Gu Mi
Employment - Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly; Lilly (I)
 
Jin Jin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
David Raymond Ferry
Employment - Lilly
Leadership - Lilly
Stock and Other Ownership Interests - Lilly
 
Charles S. Fuchs
Consulting or Advisory Role - Agios; Bayer; Dicerna; Entrinsic Health; Five Prime Therapeutics; Genentech/Roche; Gilead Sciences; KEW; Lilly; Merck; Merrimack; Sanofi; Taiho Pharmaceutical
 
Luis G. Paz-Ares
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Takeda